by divibasicbldev | Sep 14, 2026 | Press Releases
– Pasithea has been selected to present cutaneous neurofibromas (CN) clinical data in an oral presentation – Pasithea has been selected to present plexiform neurofibromas (PN) clinical data in a poster presentation – The European Neurofibromatosis...
by divibasicbldev | Sep 3, 2026 | Press Releases
— Company will hold one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference (September 9-11) and will present at the H.C. Wainwright 28th Annual Global Investment Conference (September 14-16) — MIAMI, Sept. 03, 2026 (GLOBE...
by divibasicbldev | Jul 21, 2026 | Press Releases
— Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presented Friday, October 23, 2026 — Full abstract will be...
by divibasicbldev | Jul 8, 2026 | Press Releases
July 16 in Boston, management will engage with investors and industry participants at the healthcare-focused event covering neuropsychiatry, neurodegeneration, neuromuscular disease, ophthalmology, and neuroimmunologyMIAMI, July 08, 2026 (GLOBE NEWSWIRE) —...
by divibasicbldev | Jun 30, 2026 | Press Releases
— Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, with all treatment-related adverse events (TRAEs) being Grade 1 or 2, no observed cardiac or retinal treatment-related events, and low rates of rash and...
by divibasicbldev | Jun 16, 2026 | Press Releases
— Remains on track to release interim NF1 data update in Q4 2026 —- Additional dose levels and longer treatment period added — MIAMI, June 16, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the...
